为探究急性髓系白血病（AML）病因，研究人员开展丹麦 AML 空间分布研究。分析 2000 - 2020 年数据后发现，丹麦 AML 呈均匀分布，无高风险教区。这表明居住地不影响 AML 发病风险，为后续研究提供重要依据。

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

结果显示该方案总缓解率达 92.7%，毒性较低。这为 AML 治疗提供了新选择。 在血液疾病的治疗领域，急性髓系白血病（Acute Myeloid Leukemia，AML）一直是个棘手的难题。传统上，年轻或身体状况较好的 AML 患者会采用 “7 + 3” 方案进行强化诱导治疗，也就是将蒽环类 ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...